Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunome Inc (NQ: IMNM )

15.29 -0.21 (-1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome Inc

< Previous 1 2 3 Next >
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Immunome to Present at the Stifel 2023 Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Inc. (NASDAQ: IMNM) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
From Immunome, Inc.
Via Business Wire
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Exposures Product Safety
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
From Immunome
Via Business Wire
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome to Present at 13th Annual World ADC London Conference
From Immunome, Inc.
Via Business Wire
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
From Immunome, Inc.
Via Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Immunome, Inc.
Via Business Wire
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
From Immunome, Inc.
Via Business Wire
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Jefferies Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
From Immunome, Inc.
Via Business Wire
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
From Immunome, Inc.
Via Business Wire
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.